Effect of HIV Type 1 Subtype on Virological and Immunological Response to Combination Antiretroviral Therapy: Evidence for a More Rapid Viral Suppression for Subtype A Than Subtype B-Infected Greek Individuals

Abstract

Whether response to combination antiretroviral therapy (cART) differs between those infected with HIV-1 subtype A or B remains unclear. We compared virological and immunological response to cART in individuals infected with subtype A or B in an ethnically homogeneous population. Data derived from the Athens Multicenter AIDS Cohort Study (AMACS) and analysis were restricted to those of Greek origin. Time to virological response (confirmed HIV-RNA <500 copies/ml) and time to failure (>500 copies/ml at any time or no response by month 6) were analyzed using survival models and CD4 changes after cART initiation using piecewise linear mixed effects models. Of the 571 subjects included in the analysis, 412 (72.2%) were infected with subtype B and 159 (27.8%) with subtype A. After adjusting for various prognostic factors, the rate of virological response was higher for those infected with subtype A versus B (adjusted HR: 1.35; 95% CI: 1.08-1.68; p=0.009). Subtype A was also marginally associated with a lower hazard of virological failure compared to subtype B (HR=0.73; 95% CI: 0.53-1.02; p=0.062). Further adjustment for treatment adherence did not substantially changed the main results. No significant differences were observed in the rates of CD4 increases by subtype. The overall median (95% CI) CD4 increase at 2 years of cART was 193 (175, 212) cells/μl. Our study, based on one of the largest homogeneous groups of subtype A and B infections in Europe, showed that individuals infected with subtype A had an improved virological but similar immunological response to cART compared to those infected with subtype B.

HIV‐1 genotype is independently associated with immunodeficiency progression among Chinese men who have sex with men: an observational cohort study

“…In addition, the increasing genetic heterogeneity of HIV‐1 worldwide might have consequences for virological and immunological responses to antiretroviral therapy (ART), which may vary by HIV‐1 subtype or genotype, and are of high clinical relevance. Improved virological but similar immunological responses have been observed among patients infected with non‐B clades or different recombinant forms versus subtype B . In particular, those infected with HIV‐1 subtype A or CRF02_AG had better outcomes than those infected with subtype B .…”

Virologic outcomes in early antiretroviral treatment: HPTN 052

“…20 Previous studies have reported more rapid viral suppression in individuals with certain HIV subtypes. 21,22 …”

Molecular epidemiology of HIV-1 infection in Europe: An overview

“…Over the last 15 years, the molecular epidemiology of different HIV-1 subtypes and CRFs, referred to hereafter as HIV-1 clades, in Europe has significantly changed becoming more heterogeneous Hemelaar et al, 2011). The increasing complexity raises plausible questions about potential issues in diagnosis, clinical management and even in pathogenesis (Camacho, 2006;Chaix et al, 2013;Easterbrook et al, 2010;Geretti et al, 2009;Hemelaar, 2013;Paraskevis et al, 2013b;Santoro and Perno, 2013;Scherrer et al, 2011;Siemieniuk et al, 2013;Touloumi et al, 2013). Investigation of the European HIV-1 epidemic by means of molecular epidemiology provides valuable information to investigate and monitor the epidemic's dynamics over time (Frost and Pillay, 2015;Kuhnert et al, 2014;Pybus and Rambaut, 2009;Stadler and Bonhoeffer, 2013;Stadler et al, 2012).…”